Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by Claridgeon Jun 01, 2019 10:43am

126 Views

Post# 29791122

Analysts coverage around the corner

We're getting closer and closer to analysts coverage

Normal part of the process, considering p#5 and p#6 12-month data, all that's coming in June and taking into consideration upcoming Ph. 2b 3-month interim data around October from the first UHN cohort.

May 30, 2019

University Health Hospital ("UHN") is the first site to obtain REB approval and commence Study II and is currently screening patients for enrollment in Study II.

The Company is currently working with 3 additional institutional clinical oncology sites, already in the final negotiation phases with the Company, for commencing Study II in their respective organization in 3Q 2019.

Theralase has confirmed a conference call with the Food and Drug Administration ("FDA") to discuss the design and endpoints of Study II, via a Pre-Investigational New Drug ("PIND") meeting in late June 2019. Pending completion of this conference call, the Company plans to submit an Investigational New Drug ("IND") application to the FDA and subject to their final review and approval, the Company will commence on-boarding institutional clinical oncology sites in the United States for Study II.